


CERTIFICATE OF MAILING  
UNDER 37 CFR 1.8(a)

IPW



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MAIL STOP IDS, Commissioner of Patents and Trademarks, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on

28 JAN 2005  
HUESCHEN AND SAGE

Diane L. Newton  
Dated: 28 JAN 2005

MERZ 35 /dln

\* \* \* \* \*

Applicant : Khalid IQBAL and Inge GRUNDKE-IQBAL  
Serial No. : 10/622,163  
Filed : 17 JUL 2003  
Title : NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN TAU

\* \* \* \* \*

Honorable Commissioner of Patents and Trademarks  
ALEXANDRIA, VA 22313-1450

COMMUNICATION COVERING TRANSMITTAL OF INFORMATION  
DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97 AND 1.98

Sir:

Herewith, in accord with the foregoing regulations, please find an Information Disclosure Statement which, it is respectfully submitted, should materially advance and accelerate the prosecution of the above-identified application. Attached hereto is a Form PTO-1449 and copies of the documents listed thereon.

As will be noted, this Information Disclosure Statement calls a number of prior art references, which might be considered relevant, to the attention of the Office. The fact that these are in fact "Prior Art" and/or relevant to the prosecution is, however, not admitted. It is understood that, during examination, the Office will make an independent search and will identify any relevant prior art under 37 CFR § 1.104(a).

Entry of this Information Disclosure Statement into the file of this application, initialing of each reference entry, making all of the references called

to the Office's attention therein of record, and favorable action on the merits of this application are all respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By:   
G. PATRICK SAGE

Dated: January 28, 2005

Customer No.: 25,666  
500 Columbia Plaza  
350 East Michigan Ave.  
Kalamazoo, MI 49007  
(269) 382-0030

Enclosure: Postal Card Receipt  
Form PTO-1449 listing references, and copies of each reference.


\* \* \* \* \*

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR DEFECT IN THE ATTACHED CHECK, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.

PTO-1449

## LIST OF PRIOR ART CITED BY APPLICANT

SHEET 1 OF

ATTY. DOCKET NO.  
MERZ 35

SERIAL NO. 10/622,163

APPLICANT  
Khalid IQBAL, et al.FILING DATE  
17 JUL 2003

GROUP

## U.S. PATENT DOCUMENTS

Examiner Initial	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
A	5,614,560	25 MAR 1997	Lipton			
B	5,061,703	29 OCT 1991	Schatton, et al.			

## FOREIGN PATENT DOCUMENTS

C	DOCUMENT NUMBER WO92/17168A	DATE 15 OCT 1992	COUNTRY WO	CLASS	SUB-CLASS	TRANSLATION	YES	NO
						YES		
D	WO01/89448A	29 NOV 2001	WO			YES		
E	WO99/01416A	14 JAN 1999	WO			YES		

## OTHER PRIOR ART

F	Naskar, Rita et al., "Phenytoin blocks retinal ganglion cell death after partial optic nerve crush", Experimental Eye Research, vol. 74, no. 6, June 2002 (2002-06), pages 747-752
G	Schuettauf, Frank et al., "Effects of anti-glaucoma medications on ganglion cell survival: The DBA/2J mouse model.", Vision Research, vol. 42, no. 20, September 2002 (2002-09), pages 2333-2337
H	Wenk et al., "neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites", European Journal of Pharmacology, Amsterdam, NL, vol. 347, 1998, pages 183-187
I	Naish, Hywel J., et al.: "Effect of low-affinity NMDA receptor antagonists on electrical activity in mouse cortical slices", European Journal of Pharmacology, vol. 443, no. 1-3, 17 MAY 2002 (2002-05-17), pages 79-83
J	Parsons, C. G. et al: "Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists: In vitro characterisation", Amino Acids (Vienna), vol. 19, no. 1, 2000, pages 157-166
K	International Search Report for PCT/US03/22362, eleven (11) pages

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.